Volume 1.07 | Feb 26

Prostate Cell News 1.07, February 26, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Statins Inhibit Inflammation Within Prostate Tumors
A new study from Duke University Medical Center shows that statins significantly lower the degree of inflammation within prostate tumors. [Press release from Duke University discussing online prepublication in Cancer Epidemiology, Biomarkers & Prevention]

Watch Procedure Now  
Detect 7x More Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies
 
 
CLICK HERE TO LEARN HOW STEMCELL Technologies Inc
 



SCIENCE NEWS

Substance Found in High-Fiber Foods Blocks Major Cancer Pathway
Inositol hexaphosphate, found in high concentrations in whole grains and legumes, blocks a pathway some cancer cells use to multiply, recruit blood vessels and keep from dying. [University of Colorado Press Release]

New Tool Illuminates Connections Between Stem Cells and Cancer
Researchers have been able to break apart human prostate tissue, extract the stem cells in that tissue, and alter those cells genetically so that they spur cancer. [EurekAlert! Press Release]

Aldefluor_645x110_v01




CURRENT PUBLICATIONS

LABORATORY RESEARCH

Consolidation of the Cancer Genome into Domains of Repressive Chromatin by Long-Range Epigenetic Silencing (LRES) Reduces Transcriptional Plasticity
By creating an integrated prostate cancer epigenome map using tiling arrays, researchers show that contiguous regions of gene suppression commonly occur through long-range epigenetic silencing. [Nat Cell Biol]

Molecular Profiling Uncovers a p53-Associated Role for miR-31 in Inhibiting the Proliferation of Serous Ovarian Carcinomas and Other Cancers
Findings reveal that loss of miR-31 is associated with defects in the p53 pathway and functions in serous ovarian cancer and other cancers, suggesting that patients with cancers deficient in p53 activity might benefit from therapeutic delivery of miR-31. [Cancer Res]

Potentiation of TNF-(Alpha)-Induced Tumor Cell Apoptosis by a Small-Molecule Inhibitor for Anti-Apoptotic Protein hPEBP4
Data suggest that IOI-42, as the first chemical inhibitor of anti-apoptotic protein hPEBP4, may serve as a potential antitumor drug by sensitizing tumor cells to apoptotic inducers. [J Biol Chem]

Cytotoxic Effects Induced by Docetaxel, Gefitinib, and Cyclopamine on Side Population and Nonside Population Cell Fractions from Human Invasive Prostate Cancer Cells
Observations suggest that epidermal growth factor receptor and sonic hedgehog cascades may represent the potential therapeutic targets of great clinical interest to eradicate the total prostate cancer cell mass and improve the current docetaxel-based therapies against locally advanced and invasive prostate cancers, and thereby prevent metastases and disease relapse. [Mol Cancer Ther]

miR-24 Regulates Apoptosis by Targeting the Open Reading Frame (ORF) Region of FAF1 in Cancer Cells
Researchers found that miR-24 regulates apoptosis by targeting FAF1 in cancer cells. These findings suggest that miR-24 could be an effective drug target for treatment of hormone-insensitive prostate cancer or other types of cancers. [PLoS ONE]

MYC Overexpression Induces Prostatic Intraepithelial Neoplasia and Loss of Nkx3.1 in Mouse Luminal Epithelial Cells
Using immunohistochemistry to localize MYC expression in Lo-MYC transgenic mice, researchers show that morphological and molecular alterations characteristic of high grade prostatic intraepithelial neoplasia arise in luminal epithelial cells as soon as MYC overexpression is detected. [PLoS ONE]

The Transcriptional Regulation of miR-21, Its Multiple Transcripts, and Their Implication in Prostate Cancer
Studies suggest a model where miR-21 contributes to androgen-dependent and androgen-independent prostate cancer growth. [Cell Cycle]

CLINICAL RESEARCH

Risk Factors for Prostate Cancer Detection After a Negative Biopsy: A Novel Multivariable Longitudinal Approach
Piecewise exponential models provide an approach to longitudinal analysis of prostate cancer risk that allows clinicians to see the interplay of risk factors as they unfold over time for individual patients. [J Clin Oncol]

Impact of Ethnicity on Primary Treatment Choice and Mortality in Men With Prostate Cancer: Data From CaPSURE
There is a statistically significant difference in primary treatment for prostate cancer between African American and white men with similar risk profiles. [J Clin Oncol]

A Randomized Phase II Trial of Mitoxantrone, Estramustine and Vinorelbine or Bcl-2 Modulation with 13-Cis Retinoic Acid, Interferon and Paclitaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer: ECOG 3899
Treatment with estramustine and vinorelbine was well tolerated and demonstrated clinical activity in patients with castrate-resistant prostate cancer. Given the adverse effect of 13-cis retinoic acid/interferon-alpha2b with paclitaxel on quality of life, the study of other novel agents that target Bcl-2 family proteins is warranted. [J Transl Med]


INDUSTRY NEWS

Adamis Pharmaceuticals Signs Agreement to Acquire Prostate Cancer Drug Candidates
Adamis Pharmaceuticals Corporation announced the signing of a definitive agreement to acquire exclusive license agreements covering three small molecule compounds, named CPC-100, CPC-200 and CPC-300, for the potential treatment of human prostate cancer, from privately-held Colby Pharmaceuticals, in exchange for shares of Adamis stock. [Yahoo Finance]

Dendreon 4Q Loss Widens As Costs Surge; Shares Rise >DNDN
Dendreon Corporation’s (DNDN) fourth-quarter loss widened as the cancer-vaccine specialist incurred sharply higher costs as the company continues working on its Provenge prostate cancer drug. [The Wall Street Journal]

Kinex Pharmaceuticals Initiates a Phase II Clinical Trial of KX2-391 in Patients with Prostate Cancer
Kinex Pharmaceuticals opened a Phase II clinical trial to evaluate the safety and efficacy of KX2-391 in patients with bone-metastatic, castrate-resistant prostate cancer who have not had prior chemotherapy. [Kinex Pharmaceuticals Press Release]


POLICY NEWS

Review Considerations for Applications and Awards Under the New NIH Guidelines for Human Stem Cell Research (NOT-OD-10-056) [National Institutes of Health, United States]

Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (Parent F31) (PA-10-108) [National Institutes of Health, United States]

Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Postdoctoral Fellows (Parent F32) (PA-10-110) [National Institutes of Health, United States]

Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Senior Fellows (Parent F33) (PA-10-111) [National Institutes of Health, United States]

A Centralized Protein Sequence and Function Resource (U41) (RFA-HG-10-004) [National Human Genome Research Institute, United States]

2010 Meeting Materials, Vaccines and Related Biological Products Advisory Committee [Food and Drug Administration, United States]


EVENTS

2010 Genitourinary Cancers Symposium: Progress in Multidisciplinary Management
March 5-7, 2010
San Francisco, United States

American Association for Cancer Research (AACR) 101st Annual Meeting
April 17-21, 2010
Washington, DC, United States

American Urological Association (AUA) 2010 Annual Meeting
May 29-June 3, 2010
San Francisco, United States

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

21st Meeting of the European Association for Cancer Research (EACR) 
June 26-29, 2010
Oslo, Norway

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

2010 World Cancer Congress
August, 18-21, 2010
Beijing, China


Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

 

JOB OPPORTUNITIES

Manufacturing Sciences Technologist – Cell Culture (STEMCELL Technologies)

Research & Development Technologist (STEMCELL Technologies)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.


 

 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

 

Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us